DE602006012864D1 - Gewebeinhibitor für metalloproteinasen (timp) gebunden an einen glycosylphosphatidylinositol (gpi-) anker zur behandlung von hautläsionen - Google Patents
Gewebeinhibitor für metalloproteinasen (timp) gebunden an einen glycosylphosphatidylinositol (gpi-) anker zur behandlung von hautläsionenInfo
- Publication number
- DE602006012864D1 DE602006012864D1 DE602006012864T DE602006012864T DE602006012864D1 DE 602006012864 D1 DE602006012864 D1 DE 602006012864D1 DE 602006012864 T DE602006012864 T DE 602006012864T DE 602006012864 T DE602006012864 T DE 602006012864T DE 602006012864 D1 DE602006012864 D1 DE 602006012864D1
- Authority
- DE
- Germany
- Prior art keywords
- gpi
- timp
- treatment
- cancer
- anchored
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 231100000444 skin lesion Toxicity 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 abstract 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 abstract 1
- 208000007660 Residual Neoplasm Diseases 0.000 abstract 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 abstract 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000009702 cancer cell proliferation Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002271 resection Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Marine Sciences & Fisheries (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05020462A EP1764372B1 (de) | 2005-09-20 | 2005-09-20 | Gewebeinhibitor für Metalloproteinasen (TIMP) gebunden an ein Glycosylphosphatidylinositol (GPI-) Anker zur Behandlung von Krebs |
| PCT/EP2006/009145 WO2007039109A1 (en) | 2005-09-20 | 2006-09-20 | Tissue inhibitor of metalloproteinases (timp) linked to glycosylphosphatidylinositol (gpi) -anchors for treatment of cancer and skin lesions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602006012864D1 true DE602006012864D1 (de) | 2010-04-22 |
Family
ID=35456001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005015973T Active DE602005015973D1 (de) | 2005-09-20 | 2005-09-20 | Gewebeinhibitor für Metalloproteinasen (TIMP) gebunden an ein Glycosylphosphatidylinositol (GPI-) Anker zur Behandlung von Krebs |
| DE602006012864T Active DE602006012864D1 (de) | 2005-09-20 | 2006-09-20 | Gewebeinhibitor für metalloproteinasen (timp) gebunden an einen glycosylphosphatidylinositol (gpi-) anker zur behandlung von hautläsionen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005015973T Active DE602005015973D1 (de) | 2005-09-20 | 2005-09-20 | Gewebeinhibitor für Metalloproteinasen (TIMP) gebunden an ein Glycosylphosphatidylinositol (GPI-) Anker zur Behandlung von Krebs |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9255139B2 (de) |
| EP (2) | EP1764372B1 (de) |
| JP (2) | JP5645362B2 (de) |
| CN (1) | CN101268102B (de) |
| AT (2) | ATE439383T1 (de) |
| AU (1) | AU2006299179B2 (de) |
| BR (2) | BRPI0616093A2 (de) |
| CA (2) | CA2860269C (de) |
| DE (2) | DE602005015973D1 (de) |
| DK (2) | DK1764372T3 (de) |
| ES (2) | ES2331252T3 (de) |
| HK (1) | HK1112923A1 (de) |
| IL (2) | IL189924A (de) |
| RU (2) | RU2428479C2 (de) |
| SG (1) | SG173367A1 (de) |
| WO (1) | WO2007039109A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2595778A1 (en) | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | Anti-muc1 .alpha..beta. antibodies |
| TR201815580T4 (tr) * | 2007-08-22 | 2018-11-21 | Noveome Biotherapeutics Inc | Yaraları iyileştirmeye yönelik çözelti bileşimleri ve bunların kullanımlarını içeren yeni selüler faktör. |
| EP2143442A1 (de) * | 2008-07-11 | 2010-01-13 | Peter Jon Nelson | Behandlung fester Tumore mit Metallproteinase-Gewebehemmern |
| EP2364444A4 (de) * | 2008-10-21 | 2012-08-08 | Astute Medical Inc | Verfahren und zusammensetzungen für die diagnose und prognose von nierenschädigung und nierenversagen |
| EP2324847A1 (de) | 2009-11-24 | 2011-05-25 | Peter Jon Nelson | Beschleunigung der Wundheilung durch einen Gewebeinhibitor der Metalloproteinasen verbunden mit Glycosylphosphatidylinositolankern |
| CA2804297A1 (en) | 2010-06-23 | 2011-12-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2015306608B2 (en) * | 2014-08-27 | 2020-03-05 | Amgen Inc. | Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods |
| JP6128700B2 (ja) * | 2015-05-21 | 2017-05-17 | 株式会社サンセイアールアンドディ | 遊技機 |
| CN105601733B (zh) * | 2016-02-01 | 2018-11-16 | 南通大学 | 抗CAV的多肽类似物和对应的cDNA及应用 |
| WO2018087757A1 (en) * | 2016-11-09 | 2018-05-17 | The National Institute for Biotechnology in the Negev Ltd. | Matrix metalloproteinase inhibitors and methods of use thereof |
| JP2020505069A (ja) * | 2017-01-25 | 2020-02-20 | テッサ・セラピューティクス・リミテッド | ＴＧＦ−βデコイ受容体 |
| CN110431422A (zh) | 2017-02-06 | 2019-11-08 | 机敏医药股份有限公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| US11058804B2 (en) * | 2017-06-13 | 2021-07-13 | Ethicon Llc | Surgical fastener device for the prevention of ECM degradation |
| CN109422816B (zh) * | 2017-08-25 | 2020-11-20 | 诺未科技（北京）有限公司 | 一种靶向次级淋巴组织的肝癌疫苗 |
| CN107961394B (zh) * | 2017-10-27 | 2020-10-13 | 南开大学 | 基于三元融合蛋白的抗hpv宫颈护创敷料设计 |
| KR102111025B1 (ko) * | 2018-06-05 | 2020-05-15 | 고려대학교 산학협력단 | 신경줄기세포 배양액을 유효성분으로 함유하는 항노화 또는 주름억제용 화장료 조성물 및 이의 제조 방법 |
| KR102081239B1 (ko) * | 2018-09-10 | 2020-02-25 | 고려대학교 산학협력단 | Timp-1 및 timp-2를 유효성분으로 함유하는 기형종 형성 및 성장 억제용 조성물 |
| CN109279627B (zh) * | 2018-11-09 | 2023-12-05 | 中盐枣阳盐化有限公司 | 一种盐硝固体分离工艺及化工装置 |
| US20220213170A1 (en) * | 2019-05-29 | 2022-07-07 | Hubro Therapeutics As | Peptides |
| WO2021087839A1 (zh) * | 2019-11-07 | 2021-05-14 | 武汉华大吉诺因生物科技有限公司 | 肿瘤特异性多肽序列及其应用 |
| CN113832115A (zh) * | 2021-08-25 | 2021-12-24 | 居颂光 | 融合基因ril-7联合ccl19重组溶瘤牛痘病毒及其在制备抗肿瘤药物中的应用 |
| GB202114441D0 (en) | 2021-10-08 | 2021-11-24 | Reneuron Ltd | Proteins and extracellular vesicles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544761B2 (en) * | 1994-12-13 | 2003-04-08 | Human Genome Sciences, Inc. | Human tissue inhibitor of metalloproteinase-4 |
| CN1129666C (zh) * | 1994-12-13 | 2003-12-03 | 人体基因组科学有限公司 | 金属蛋白酶－4的人组织抑制剂 |
| WO2001057068A1 (en) * | 2000-02-01 | 2001-08-09 | The Austin Research Institute | Mucin-1 derived antigens and their use in immunotherapy |
| US20020010162A1 (en) * | 2000-03-02 | 2002-01-24 | Raul Fleischmajer | Treatment of psoriasis with matrix metalloproteinase inhibitors |
| CN1338305A (zh) * | 2000-08-21 | 2002-03-06 | 杭州泰士生物科技有限公司 | 基质金属蛋白酶组织抑制剂预防和治疗血管损伤后再狭窄 |
| CN1398639A (zh) * | 2001-02-19 | 2003-02-26 | 王明生 | Timp－4基因作为制备临床治疗心血管和疤痕修复药中的应用 |
| SE0200667D0 (sv) * | 2002-03-05 | 2002-03-05 | A & Science Invest Ab | Novel use of cytokine inhibitors |
| CN1162185C (zh) * | 2002-11-01 | 2004-08-18 | 北京深文科技开发有限责任公司 | 基质金属蛋白酶组织抑制剂在制备预防和治疗关节炎病药的应用 |
-
2005
- 2005-09-20 ES ES05020462T patent/ES2331252T3/es active Active
- 2005-09-20 EP EP05020462A patent/EP1764372B1/de not_active Not-in-force
- 2005-09-20 AT AT05020462T patent/ATE439383T1/de active
- 2005-09-20 DK DK05020462T patent/DK1764372T3/da active
- 2005-09-20 DE DE602005015973T patent/DE602005015973D1/de active Active
-
2006
- 2006-09-20 CA CA2860269A patent/CA2860269C/en not_active Expired - Fee Related
- 2006-09-20 BR BRPI0616093-0A patent/BRPI0616093A2/pt active Search and Examination
- 2006-09-20 WO PCT/EP2006/009145 patent/WO2007039109A1/en active Application Filing
- 2006-09-20 DK DK06805780.1T patent/DK1937725T3/da active
- 2006-09-20 SG SG2011050408A patent/SG173367A1/en unknown
- 2006-09-20 AU AU2006299179A patent/AU2006299179B2/en not_active Ceased
- 2006-09-20 DE DE602006012864T patent/DE602006012864D1/de active Active
- 2006-09-20 CN CN2006800343518A patent/CN101268102B/zh not_active Expired - Fee Related
- 2006-09-20 BR BRPI0622293-5A patent/BRPI0622293A2/pt not_active IP Right Cessation
- 2006-09-20 CA CA2622042A patent/CA2622042C/en not_active Expired - Fee Related
- 2006-09-20 US US11/992,213 patent/US9255139B2/en not_active Expired - Fee Related
- 2006-09-20 AT AT06805780T patent/ATE460432T1/de active
- 2006-09-20 RU RU2008108940/10A patent/RU2428479C2/ru not_active IP Right Cessation
- 2006-09-20 JP JP2008531605A patent/JP5645362B2/ja not_active Expired - Fee Related
- 2006-09-20 ES ES06805780T patent/ES2342425T3/es active Active
- 2006-09-20 EP EP06805780A patent/EP1937725B1/de not_active Not-in-force
-
2008
- 2008-03-04 IL IL189924A patent/IL189924A/en not_active IP Right Cessation
- 2008-07-17 HK HK08107922.0A patent/HK1112923A1/xx not_active IP Right Cessation
-
2011
- 2011-05-10 RU RU2011118511/10A patent/RU2011118511A/ru not_active Application Discontinuation
- 2011-05-12 IL IL212867A patent/IL212867A/en not_active IP Right Cessation
-
2013
- 2013-06-06 JP JP2013119610A patent/JP2013240326A/ja active Pending
-
2016
- 2016-01-19 US US15/000,928 patent/US20160271234A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006012864D1 (de) | Gewebeinhibitor für metalloproteinasen (timp) gebunden an einen glycosylphosphatidylinositol (gpi-) anker zur behandlung von hautläsionen | |
| Feng et al. | Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate | |
| Yun et al. | JPH203, an L-type amino acid transporter 1–selective compound, induces apoptosis of YD-38 human oral cancer cells | |
| AR120138A1 (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
| CY1113094T1 (el) | Ανοσοσφαιρινες κατευθυνομενες εναντι nogo | |
| UY32455A (es) | Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia | |
| AR037666A1 (es) | Metodo para la identificacion de enzimas marcadores tumorales | |
| ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
| MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
| NI201200155A (es) | Proteína de fusión robo1 - fc y su utilización en el tratamiento de tumores | |
| CU20120126A7 (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| WO2008091620A3 (en) | Combination therapy comprising romidepsin and i.a. bortezomib | |
| WO2010045586A3 (en) | Muc-1 cytoplasmic domain peptides as inhibitors of cancer | |
| CL2008001906A1 (es) | Compuestos inhibidores de calicreina 7 derivados del acido pirrolidin-1,2-dicarboxilico, composiciones que los contienen y uso para el tratamiento de enfermedades inflamatoria, hipeproliferativas y/o pruriticas de ka piel; cristal de calicreina 7 y metodo para identificar ligandos de calicreina 7. | |
| EA201491259A1 (ru) | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания | |
| GT200800102A (es) | Compuestos y metodos para inhibir la interaccion de proteinas bcl con moleculas de enlace | |
| UY28801A1 (es) | Derivados radiohalogenados de benzamida y su uso en el diagnóstico y la terapia de tumores | |
| BR112018077219A2 (pt) | matriz de peptídeo de automontagem para a prevenção de estenose esofágica após dissecção endoscópica | |
| CY1109524T1 (el) | Τροποποιημενη ανθρωπινη δισμουταση υπεροξειδιου μαγγανιου και οι χρησεις της | |
| ZA202201889B (en) | A urokinase plasminogen activator receptor-targeting peptide | |
| PH12020550042A1 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| Hap et al. | Control of active B and L cathepsins in tissues of colorectal cancer using cystatins isolated from chicken egg proteins: in vitro studies | |
| GT201200317A (es) | "metodos para la identificacion de composiciones que alteran la expresion de genes y proteinas en una celula de planta de tipo silvestre | |
| FR2947455B1 (fr) | La dermaseptine b2 comme inhibiteur de la croissance tumorale | |
| CY1123986T1 (el) | Νεες συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |